Prosthetic valves thrombosis at mitral position: clinical recognition and surgical management

Vichai Benjacholamas* Meunmai Sanpradit*
Chawalit Ongcharit* Yothin Kurowat*
Somsak Watanapat* Kittichai Luengtaviboon*


During a 3-year period in Chulalongkorn Hospital, there were nine patients with prosthetic valve thrombosis at mitral position. Four of them were Sorin valves, another four were Carbomedics valves and the last was Metronic-Hall valve. Most of the patients had an acute exacerbation of heart failure and developed pulmonary edema. Prothrombin time was in the therapeutic range at the time of admission in 5 of the 9 patients. Echocardiogram was done in five patients to confirm the diagnosis. One patients died before reoperation. Emergency reoperation were undertaken in 8 patients for re-replacement of the prosthetic valves. Operative mortality rate was 37.5 per cent (3/8). These findings emphasize the importance of considering the diagnosis of thrombosed heart valves in patients with prosthetic heart valve who are seen with acute heart failure and pulmonary edema.

Key words: Prosthetic valve thrombosis, Mechanical valve thrombosis.

Reprint request: Benjacholamas B, Department of Surgery, Faculty of medicine, Chulalongkorn University, Bangkok 10330, Thailand. Received for publication. October 30, 1993.

* Department of Surgery, Faculty of Medicine, Chulalongkorn University.
ผู้ป่วยจำนวน 9 ราย มีลิมิตข้อตัวผิดปกติที่สามารถไกล่เกลี่ยให้ผ่านทางหลอดเลือดได้หลังจากการผ่าตัด เปลี่ยนเส้นหัวใจ ที่โรงพยาบาลจุฬาลงกรณ์ ในช่วงระยะเวลา 3 ปี ลิมิตข้อตัวผิดปกติที่เกิดจากการผ่าตัดเป็นลิมิต หัวใจเทียม Sorin 4 ราย เป็นลิมิตหัวใจเทียม Caromedics 4 ราย และอีก 1 รายเป็นลิมิตหัวใจเทียม Metronic-Hall ผู้ป่วยทั้งหมดมีอาการของหัวใจเต้นเร็วและพบมีการปอดกว้างน้อยอย่างกระทันหันผู้ป่วย 5 ใน 9 รายมีระดับของ Prothrombin time อยู่ในช่วงการรักษาที่ยอมรับ ผู้ป่วย 5 รายได้รับการตรวจด้วยเครื่องตรวจเส้นเลือดแดงประเภทหัวใจ (Echocardiogram) เพื่อถูกยันการรักษา ผู้ป่วยรายหนึ่งเร่งแก้ปัญหาที่จะได้รับการผ่าตัดแก้ไข สำนวนป่วยอีก 4 รายได้รับการผ่าตัดลิมิตเส้นหัวใจเทียมอีกที่ ผู้ป่วยผิดปกติอีก 3 รายได้รับการผ่าตัดเปลี่ยนเส้นหัวใจเทียมอีกที่ ผู้ป่วยผิดปกติอีก 3 รายได้รับการผ่าตัดเปลี่ยนเส้นหัวใจเทียมอีกที่ ผู้ป่วยผิดปกติอีก 3 รายได้รับการผ่าตัดเปลี่ยนเส้นหัวใจเทียมอีกที่.
A growing number of patients have prolonged survival after cardiac valve replacement. Long life-span increases the eventual risk of development of complication in these patients. Prosthetic valve thrombosis is one of the serious complication with high mortality concerning reoperation in these critically ill patients.\(^1\)\(^-\)\(^7\) The incidence of thrombosis is highest at mitral position.\(^2\)\(^,\)\(^4\)\(^,\)\(^5\)\(^,\)\(^6\) Noninvasive investigations such as echocardiography have been recommended in the diagnostic evaluation of prosthetic valve thrombosis.\(^7\)\(^-\)\(^9\) In this communication, we present 9 patients with prosthetic valve thrombosis at mitral position who had been treated in our hospital.

**Material and methods**

From October 1988 to September 1991, nine patients with prosthetic valves thrombosis were recognized and underwent surgical management. There were 4 Sorin valves, 4 CarboMedic valves and one Metronic-Hall valve. (Table 1). Since 1981, 608 prosthetic heart valves were replaced in mitral position. There were 253 Metronic-Hall valves, 202 Starr-Edwards cage and ball valves, 108 Sorin valves, 42 CarboMedics valves, and 3 St.Jude valves. (Table 1) All of them were placed on an anticoagulation program with warfarin. The dosage was adjusted by frequent measurement of the prothrombin time. Anticoagulation was considered adequate when the prothrombin time could be maintained between 50 to 75% of the normal value. The over all incidence of prosthetic valve thrombosis is 1.5% (9 in 608 patients) at mitral position. The incidence of thrombosis in each valves were 0%, 0%, 0.4%, 3.7% and 9.5% in Starr-Edwards, St. Jude, Metronic-Hall, Sorin and CarboMedics valves respectively.

**Table 1.** Prosthetic valve use for mitral valve replacement (1981-1991).

<table>
<thead>
<tr>
<th>Type of valve</th>
<th>No. of patients</th>
<th>No. of valve thrombosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medtronic-Hall</td>
<td>253</td>
<td>1(0.4%)</td>
</tr>
<tr>
<td>Starr-Edwards</td>
<td>202</td>
<td>0(0.0%)</td>
</tr>
<tr>
<td>Sorin</td>
<td>108</td>
<td>4(3.7%)</td>
</tr>
<tr>
<td>CarboMedics</td>
<td>42</td>
<td>4(9.5%)</td>
</tr>
<tr>
<td>St.Jude</td>
<td>3</td>
<td>0(0.0%)</td>
</tr>
</tbody>
</table>

**Results**

Clinical data on the 9 patients with prosthetic valve thrombosis are summarized in Table 2. All of them were female and age between 30 to 60 years (mean 43.5 years). The interval between mitral valve replacement and dysfunction of the thrombotic valve ranged from 40 days to 63 months (median time, 18 months). Systemic anticoagulation with warfarin was judged to be adequate (prothrombin time \(>=1.5\) times control) in 5 of the 9 patients at the time of diagnosis of prosthetic valve thrombosis. Four of nine patients had precipitating causes; two of them had discontinued warfarin (due to diarrhea in one and to prepare for tooth extraction in
another), one had low cardiac output after operation and the last patient had used Depo-provera (DMPA) for contraception over one year before thrombosis occurred.

**Table 2.** Summary of clinical data on patients with prosthetic valve thrombosis.

<table>
<thead>
<tr>
<th>Patients No.</th>
<th>Age</th>
<th>Sex</th>
<th>Valve type</th>
<th>PT interval from insertion to thrombosis (mo)</th>
<th>Precipitating factors</th>
<th>Echo</th>
<th>Reoperation</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>60</td>
<td>F</td>
<td>CM#29</td>
<td>&gt;=1.5</td>
<td>low CO done</td>
<td>no</td>
<td>replace</td>
<td>death</td>
</tr>
<tr>
<td>2</td>
<td>41</td>
<td>F</td>
<td>CM#29</td>
<td>&gt;=1.5</td>
<td>no done</td>
<td>replace</td>
<td>survive</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>59</td>
<td>F</td>
<td>S#29</td>
<td>&gt;=1.5</td>
<td>no done</td>
<td>replace</td>
<td>CE#27</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>32</td>
<td>F</td>
<td>S#29</td>
<td>&lt;=1.5</td>
<td>no done</td>
<td>replace</td>
<td>SE#2M</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>38</td>
<td>F</td>
<td>CM#27</td>
<td>&lt;=1.5</td>
<td>diarrhea, discontinue warfarin</td>
<td>no</td>
<td>replace</td>
<td>MH#27</td>
</tr>
<tr>
<td>6</td>
<td>35</td>
<td>F</td>
<td>S#27</td>
<td>&gt;=1.5</td>
<td>no no</td>
<td>replace</td>
<td>SE#2M</td>
<td>DOT</td>
</tr>
<tr>
<td>7</td>
<td>39</td>
<td>F</td>
<td>S#31</td>
<td>&gt;=1.5</td>
<td>no no</td>
<td>replace</td>
<td>SE#3M</td>
<td>survive</td>
</tr>
<tr>
<td>8</td>
<td>38</td>
<td>F</td>
<td>CM#25</td>
<td>&gt;=1.5</td>
<td>discontinue warfarin, prepare for tooth extraction</td>
<td>no</td>
<td>replace</td>
<td>death, ARF MH#27</td>
</tr>
<tr>
<td>9</td>
<td>30</td>
<td>F</td>
<td>MH#31</td>
<td>&lt;=1.5</td>
<td>Depo-provera (DMPA)</td>
<td>done</td>
<td>replace</td>
<td>survive</td>
</tr>
</tbody>
</table>

All patients present with symptoms of dyspnea and congestive heart failure. Chest roentgenography showed pulmonary venous congestion in all patients. The diagnosis of prosthetic valve thrombosis was made by clinical criteria in 5 patients and the other 4 had echocardiography to confirm the diagnosis. The timing of reoperation depended on the clinical condition of the patients and the time necessary for establishing the diagnosis of thrombosis of the prosthetic valve. Reoperation were performed in 8 patients except one who died before the time of reoperation. There were 2 Carpentier-edwards
bioprosthetic valves, 4 Starr-Edwards cage and ball valves and 2 Metronic-Hall valves used for rereplacement of the mitral valve 3 patients died within 7 days after reoperation, two of them could not be weaned off from cardiopulmonary bypass and another one died from acute renal failure. Operative mortality rate was 37.5% (3/8) and over all hospital mortality was 44.4% (4/9)

Nonfatal complication occurred in one patient with hemiparesis post-reoperation, and which recovered dramatically 2 months postoperatively.

Discussion

The reported incidence of prosthetic valve thrombosis are 1 to 8% depended on the valve’s design.\(^{4,5,10-18}\) In our series we found that CarboMedics valve has the highest incidence of thrombosis (9.5%), and Starr-Edwards cage and ball valve has the lowest incidence of thrombosis (0%). At operation it was found that thrombotic material grew into the hinge joint of the valve leaflets that just situated below the level of the annulus and caused dysfunction of the valve leaflets in all thrombotic Carbomedics valves. Thus we postulate that the design of the valve is of paramount importance.

Patients with prosthetic mitral valve thrombosis usually have a rapid catastrophic course. The most salient finding on clinical examination of these patients is the absence or attenuation of the prosthesis-related closing sound.

Echocardiography is very useful to confirm the diagnosis accurately especially in an experienced hand. Therewere no false negative or false positive in our series. However, we could confirm the diagnosis of the thrombotic valve by echocardiography only 5 in 9 patients, due to the fact that the other 4 patients were in poor condition and required emergency surgery. Therefore the clinical signs history and are of significance and adequate to establish the diagnosis in these critically ill patients.

Recently, some investigators reported the successful use of thrombolytic therapy to manage prosthetic mitral valve thrombosis.\(^{5,19}\) We believe that this technique has some potential hazards and therefore, we will strongly advise reoperation as the primary treatment of thrombosed prosthetic valve.

The operative mortality of reoperation for prosthetic valve thrombosis was directly related to the patient's preoperative condition and surgical experience.\(^{14,18,20}\) The high mortality rate in our series is due to the delay both in diagnosis and in referral of patients to cardiac surgical unit. Therefore, we emphasize the importance of establishing early diagnosis of thrombosed valves in patients who have prosthetic heart valve with acute congestive heart failure and pulmonary edema. Early notification to the surgical team is a life-saving.

References


18. Moreno-Cabral RJ, McNamara JJ, Mamiya RT, Brainard SC, Chung GKT. Acute


Mal Coeur Vaissd 1983 Feb; 76(2): 133-43